Antisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a Trial
According to a press release by trial sponsor Ionis, therapy was well tolerated, but trial results have yet to be released.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
In the Running: Trial Results from CTAD Conference
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
At Least We Know These Don’t Work: Negative Trials at CTAD
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
No Negativity, Please. Clinical Trial Leader Urges Focus on Learning, Progress
At recent CTAD conference, Rachelle Doody called on her colleagues to learn from failures and work together to support better drug evaluation studies.
It’s Official: CSF Aβ42 Reference Standard Will Unify Assays
Certified reference material by which companies can calibrate assays is now available worldwide.
Clinical Trials Consortium Succeeds ADCS, Focuses on Prevention
The new ACTC network will establish streamlined recruitment and startup protocols to make trials more efficient.
Society for Neuroscience Annual Meeting 2017
Tau Snapshots from Neuroscience 2017 Disturbed Sleep Exerts Toll on Memory and Neurodegeneration Gut Microbiome May Modify Neurodegeneration Is There No End to Tau’s Toxic Tricks? This year’s annual meeting drew more than 23,000 scientists and featured 1,
Disturbed Sleep Exerts Toll on Memory and Neurodegeneration
Why, hello tau! Convergence of PET and EEG research affirms that sleeping well is crucial to memory consolidation and curbing Alzheimer’s-related proteins.
Tau Snapshots from Neuroscience 2017
Novel ways to control tau captured the imaginations of scientists at the Society for Neuroscience annual meeting.
2017—A Year in Research
The Alzforum team compiles some of their favorite stories from the past year.
Is There No End to Tau’s Toxic Tricks?
At SfN 2017, some of the lesser-known tau toxicities came in for deep scrutiny.
No Man’s Land: Neither Early Success nor Failure for BAN2401
Bayesian adaptive Phase 2 trial of anti-protofibril Aβ antibody did not, as desired, deliver an accelerated result. It will now continue to its end at 18 months.
Turning Peripheral Stem Cells into Amyloid-Gobbling Brain Phagocytes
Screen identifies antibody that induces mouse bone marrow cells to differentiate and travel to the brain, where they clear plaques.
New Microglial Model May Aid Genetic Studies, Drug Screening
Microglia-like cells from blood monocytes facilitate large-scale studies.
DLB: Intepirdine a No-Go, Nelotanserin Shrouded in Controversy
Initial report touted positive exploratory results for nelotanserin, but a correction wiped out optimism.
Current Filters
No filters selected